Table 3 Hazard ratios for recurrence (TTR) and death (OS) in the pooled cohort

PODXL negative

 Treatment

  Surgery only

24 (8)

30 (19)

  Neoadjuvant chemotherapy^a

25 (12)

1.24 (0.51–3.03)

0.639

0.85 (0.31–2.39)

0.763

25 (12)

0.72 (0.35–1.50)

0.378

0.88 (0.31–2.49)

0.807

    Neoadjuvant fp + oxa ≥ 8 w^b

19 (10)

1.39 (0.55–3.52)

0.490

0.79 (0.26–2.34)

0.665

19 (9)

0.74 (0.33–1.64)

0.453

0.77 (0.25–2.34)

0.638

PODXL positive

 Treatment

  Surgery only

104 (62)

119 (93)

  Neoadjuvant chemotherapy^a

48 (13)

0.35 (0.19–0.64)

0.001

0.31 (0.16–0.59)

< 0.001

51 (20)

0.43 (0.26–0.69)

0.001

0.65 (0.38–1.10)

0.110

    Neoadjuvant fp + oxa ≥ 8 w^b

44 (10)

0.29 (0.15–0.57)

< 0.001

0.27 (0.13–0.55)

< 0.001

45 (14)

0.32 (0.18–0–56)

< 0.001

0.48 (0.26–0.90)

0.021

Entire pooled cohort

 Treatment

  Surgery only

131 (72)

152 (114)

  Neoadjuvant chemotherapy^a

102 (41)

0.64 (0.43–0.93)

0.021

0.018 ^†

1.01 (0.40–2.55)

0.986 

0.069† 

105 (49)

0.57 (0.41–0.80)

< 0.001

0.191^†

0.85 (0.40–1.81)

0.669

0.640^†

    Neoadjuvant fp + oxa ≥ 8 w^b

87 (33)

0.60 (0.40–0.91)

0.016

0.006 ^†

1.18 (0.45–3.10)

0.733   0.024 ^†

88 (36)

0.50 (0.34–0.72)

< 0.001

0.080^†

0.84 (0.37–1.94)

0.690

0.395^†